Expression and Clinical Significance of CA125, CA153 and CEA in Nipple Discharge of Breast Cancer Patients

Overview

Journal J Med Biochem

Specialty Biochemistry

Date 2024 May 3

PMID 38699697

Authors

Jun Geng

Shi Jinli

Weina Guo

Haiyan Li

Yang Dan

Yan Gao

Affiliations

Soon will be listed here.

Abstract

Background: It is an important clinical means to identify benign and malignant breast diseases caused by nipple discharge through the detection and analysis of components in nipple discharge. This study was aimed to test the expression and clinical significance of carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) and carcinoembryonic antigen (CEA) in nipple discharge of breast cancer patients.

Methods: From January 2017 to December 2018, 86 patients with invasive ductal carcinoma of the breast with nipple discharge (breast cancer group) and 50 patients with ordinary breast duct hyperplasia with nipple discharge (benign control group) were selected, and the levels of CA125, CA153 and CEA in nipple discharge and serum were detected by electrochemiluminescence immunoassay.

Citing Articles

Tumor size, HER-2 status, CA125, CEA, SII, and PNI: key predictors of pathological complete response in LABC patients.

Guo X, Wen R, Yu L, Lin H Am J Cancer Res. 2024; 14(10):4880-4895.

PMID: 39553222 PMC: 11560830. DOI: 10.62347/YAWK6271.

References

Zhang L, Chen Y, Wang K . Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2018; 43(2):135-144. DOI: 10.1016/j.currproblcancer.2018.06.001. View

Choi J, Ro J . The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol. 2020; 28(1):44-58. DOI: 10.1097/PAP.0000000000000284. View

Kamali S, Bender O, Harman Kamali G, Aydin M, Karatepe O, Yuney E . Diagnostic and therapeutic value of ductoscopy in nipple discharge and intraductal proliferations compared with standard methods. Breast Cancer. 2012; 21(2):154-61. DOI: 10.1007/s12282-012-0377-7. View

Gupta D, Mendelson E, Karst I . Nipple Discharge: Current Clinical and Imaging Evaluation. AJR Am J Roentgenol. 2020; 216(2):330-339. DOI: 10.2214/AJR.19.22025. View

Patuleia S, van Gils C, Oneto Cao A, Bakker M, van Diest P, van der Wall E . The Physiological MicroRNA Landscape in Nipple Aspirate Fluid: Differences and Similarities with Breast Tissue, Breast Milk, Plasma and Serum. Int J Mol Sci. 2020; 21(22). PMC: 7696615. DOI: 10.3390/ijms21228466. View

Hao C, Zhang G, Zhang L . Serum CEA levels in 49 different types of cancer and noncancer diseases. Prog Mol Biol Transl Sci. 2019; 162:213-227. DOI: 10.1016/bs.pmbts.2018.12.011. View

Xiang W, Lv Q, Shi H, Xie B, Gao L . Aptamer-based biosensor for detecting carcinoembryonic antigen. Talanta. 2020; 214:120716. DOI: 10.1016/j.talanta.2020.120716. View

Afsar C, Aral H, Can O, Can T, Karacetin D, Ali N . Serum fetuin-A and RANKL levels in patients with early stage breast cancer. J Med Biochem. 2023; 42(2):249-257. PMC: 10040193. DOI: 10.5937/jomb0-37386. View

Zhao S, Gai X, Wang Y, Liang W, Gao H, Zhang K . Diagnostic Values of Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 Levels in Nipple Discharge. Chin J Physiol. 2016; 58(6):385-92. DOI: 10.4077/CJP.2015.BAD336. View

10.

Jia L, Li G, Ma N, Zhang A, Zhou Y, Ren L . Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction. BMC Cancer. 2022; 22(1):760. PMC: 9281047. DOI: 10.1186/s12885-022-09864-y. View

11.

Li J, Liu L, Feng Z, Wang X, Huang Y, Dai H . Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020; 27(4):621-630. DOI: 10.1007/s12282-020-01058-3. View

12.

Li X, Dai D, Chen B, Tang H, Xie X, Wei W . Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. Dis Markers. 2018; 2018:9863092. PMC: 5954898. DOI: 10.1155/2018/9863092. View

13.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

14.

Einama T, Yamagishi Y, Takihata Y, Suzuki T, Yamasaki T, Hirose Y . Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients. Biomark Res. 2021; 9(1):78. PMC: 8555316. DOI: 10.1186/s40364-021-00335-3. View

15.

Sharma N, McMahon M, Haigh I, Chen Y, Dall B . The Potential Impact of Digital Breast Tomosynthesis on the Benign Biopsy Rate in Women Recalled within the UK Breast Screening Programme. Radiology. 2019; 291(2):310-317. DOI: 10.1148/radiol.2019180809. View